IBS

Psychedelics biotech Tryp Therapeutics (OTCQB: TRYPF) is advancing its psilocybin-based portfolio through several recent milestones. Upcoming Phase 1 For IV Psilocin First, the company received approval from the Australian Human Research Ethics Committee (HREC) for a Phase 1 study on its IV-infused...

Irritable Bowel Syndrome, or IBS, which it is commonly referred to as, plagues over 15 percent of the U.S. population. IBS patients typically visit the doctor three times more than a normal patient, and healthcare costs associated with the disease are estimated to be in the $30 billion range. It...